You are here

High-throughput Discovery of Antibodies against Understudied Membrane Proteins

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM150317-01
Agency Tracking Number: R43GM150317
Amount: $295,924.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 300
Solicitation Number: PA22-176
Solicitation Year: 2022
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-05-01
Award End Date (Contract End Date): 2024-04-30
Small Business Information
Philadelphia, PA 19104-5504
United States
DUNS: 034055645
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (215) 966-6061
Business Contact
Phone: (215) 966-6061
Research Institution

Of the 20,000 genes in the human genome, approximately 4,000 are considered “druggable” by
pharmaceuticals. However, less than 10% of these druggable proteins are actually targeted by FDA-approved
drugs. In 2014, the Illuminating the Druggable Genome (IDG) project was launched by the NIH in recognition
that there is a potentially large number of druggable targets with high therapeutic value that are undiscovered
or understudied. The IDG selected 230 G protein-coupled receptors (GPCRs) and ion channels as a focus of
their program, as these families make up the largest families of the druggable genome and have high potential
to impact human health. Due to their difficult biology, many of them are completely unexplored. To enable this
research, the IDG has called for the development of reagents such as monoclonal antibodies (MAbs) against
these 230 GPCRs and ion channels, only 10% of which currently have commercially available MAbs. A novel
approach to identify membrane protein MAbs in a high-throughput manner is needed to derive MAbs against
the entire druggable human membrane proteome.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government